Page 4 - Mark Corbae News Today

Cybrexa Therapeutics Closes $25 Million Series B Financing -Proceeds will advance the companys lead program into clinical trials- NEW HAVEN, Conn., March 10, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex Peptide Drug Conjugate (PDC) tumor targeting platform, today announced the completion of its $25 million Series B financing. The financing included HighCape Capital and new investor Elm Stre...

(1) - Cybrexa and NCI to collaborate on clinical development of Cybrexas lead candidate, CBX-12, to assess the safety and efficacy in oncology patients with solid tumors - NEW HAVEN, Conn., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex Peptide Drug Conjugate (PDC) tumor targeting platform, today announced that it has entered a Cooperative Research and Development Agreement (CRADA) w...

Sirnaomics to Present at Medical Dermatology Summit News provided by Share this article , a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced that it will be presenting results from a recently completed Phase 2a clinical study of the companys lead drug candidate, STP705, for treatment of squamous cell skin cancer, at the 19th Annual South Beach Symposium Medical Dermatology Summit. The virtual conference...

Cybrexa Therapeutics Reports Positive Results from GLP Toxicology Study of Lead Candidate CBX-12 (alphalex-exatecan) - No Unexpected Safety Findings During the Course of the Study - - On Track to File an IND in the First Quarter 2021 and Commence Phase I Trial by Mid Year 2021 - NEW HAVEN, Conn., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex Peptide Drug Conjugate (PDC) tumor target...

/PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic...

Search jobs 20-Dec-2020 Sirnaomics Reports Positive Data from Phase 2a Study of STP705 for Treatment of Squamous Cell Skin Cancer GAITHERSBURG, Md. and SUZHOU BIOBAY, China, Dec. 20, 2020 /PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced positive efficacy and safety results from a Phase 2a clinical study of the companys lea...

Press release content from PR Newswire. The AP news staff was not involved in its creation. Sirnaomics Reports Positive Data from Phase 2a Study of STP705 for Treatment of Squamous Cell Skin Cancer December 20, 2020 GMT Sirnaomics Company Logo (PRNewsfoto/Sirnaomics, Inc.) GAITHERSBURG, Md. and SUZHOU BIOBAY, China, Dec. 20, 2020 /PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today...